Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech products specialist Techne
With that in mind, let's take a closer look at Techne's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||Minneapolis (1976)|
|Market Cap||$2.85 billion|
|Industry||Life sciences tools and services|
|Trailing-12-Month Revenue||$272.64 million|
Chairman/CEO Thomas Oland (since 1985)
CFO Gregory Melsen (since 2004)
|Return on Equity (Average, Past 3 Years)||23%|
|Cash/Debt||$194.86 million / $0|
Thermo Fisher Scientific
Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.
On CAPS, 97% of the 274 members who have rated Techne believe the stock will outperform the S&P 500 going forward. These bulls include Clint35 and All-Star FAOFool, who is ranked in the top 2% of our community.
Earlier this month, Clint35 touched on Techne's attractive fundamentals: "Very impressive numbers. Great balance sheet. Pays a dividend. Still has a lot of room to grow."
Techne even boasts a whopping three-year average operating margin of 57.3%. That's much higher than that of listed rivals Abbott (20.3%), Beckman (11.4%), and Thermo Fisher (12%).
CAPS All-Star FAOFool elaborates on the Techne bull case:
Demographics ... just look at all those 'Doctor' shows on TV! We are definitely getting older as a society due to the population demographics and longer life span, but all these shows, and debate about health care, have everyone much more focused on health care. TECH is a great company to capitalize on both, given its product breadth and solid financials.
What do you think about Techne, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!